Clinical Report: Gender Differences in Cardiovascular Outcomes After CAR-T Therapy

Overview

This study evaluates sex-based differences in major adverse cardiovascular events (MACE) following chimeric antigen receptor T-cell (CAR-T) therapy.

Background

Cardiovascular complications are increasingly recognized as significant sequelae of CAR-T therapy, which is used for treating relapsed or refractory B-cell malignancies. Understanding potential sex-based differences in cardiovascular risk is crucial for optimizing patient management and improving outcomes in this growing patient population.

Data Highlights

Key Findings

• Males had a higher incidence of MACE compared to females at both 1 year and 2 years post-CAR-T therapy.
• At 1 year, the incidence of MACE was 558 events in males versus 437 in females.
• At 2 years, the incidence of MACE was 697 events in males versus 593 in females.
• Males exhibited a higher risk of all-cause mortality and cardiovascular complications such as atrial fibrillation and ventricular arrhythmias.

Clinical Implications

The study highlights the importance of considering biological sex in cardiovascular risk assessment for patients receiving CAR-T therapy. Clinicians should monitor male patients more closely for cardiovascular complications and adjust management strategies accordingly.

Conclusion

Male sex is associated with a higher risk of MACE and cardiovascular complications following CAR-T therapy.

Related Resources & Content

1. Blood Cancer Journal, 2025 -- Clarifying the Concept of 'Intention' in Survival Outcomes for Intention-to-Treat Analysis in CAR T-Cell Therapy
2. The ASCO Post, 2023 -- CAR T-Cell Therapy May Improve Quality of Life of Patients With Hematologic Malignancies
3. Bone Marrow Transplantation, 2023 -- Highlights from the 49th Annual Conference of the European Society for Blood and Marrow Transplantation
4. PubMed, 2026 -- Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association
5. Journal of Echocardiography, 2026 -- Practical guidance for echocardiography for cancer therapy-related cardiac dysfunction: 2026 focused update
6. The ASCO Post — Blood Tests Could Help Predict Which Patients With Lymphoma May Respond Poorly to CAR T-Cell Therapy
7. Guarding the heart in the era of immunotherapies: insights for cardio-oncology practice
8. Temporal trends, cardiovascular complications, and outcomes in patients receiving CAR T-cell therapy: a 6-year nationwide analysis
9. Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association - PubMed
10. Practical guidance for echocardiography for cancer therapy-related cardiac dysfunction: 2026 focused update | Journal of Echocardiography | Springer Nature Link
11. Recommended Reading - ESC Council of Cardio-Oncology
12. Cardiovascular complications in CAR T-cell therapy: Insights from a national inpatient database. | Journal of Clinical Oncology
13. Cardiac Toxicities Following Chimeric Antigen T-cell Therapy: A Post-Marketing Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
14. A retrospective pharmacovigilance analysis based on the FAERS database reveals sex-associated differences in toxicities of CAR T-cell therapy - PubMed
15. CT-048: Battle of the Sexes: The Cardioprotective Edge of Female Sex in CAR T-Cell Therapy - ScienceDirect
16. 26-A-18665-ACC SEX-BASED DIFFERENCES IN CARDIOTOXICITY AFTER CAR-T CELL THERAPY: A REAL-WORLD PROPENSITY-MATCHED ANALYSIS | JACC